POSSIBILITIES AND PROSPECTS OF DOUBLE EFFECT DRUGS APPLICATION FOR SYSTEMIC OSTEOPOROSIS PHARMACOTHERAPY OF PATIENTS WITH BONE FRACTURES

Cover Page


Cite item

Abstract

Scientific literature analysis shows that osteoporotic bone fractures appear to be actual and socially significant problem of modern medicine. Patients’ treatment with this pathology should be complex and include osteoporosis pharmacotherapy. The perspective drug for this case is strontium ranelate. Experimental and clinic researches show its positive influence on osteoporotic fractures healing, possibility to increase implants stability by osteosynthesis, moreover it can improve microarchitectonics of bone tissue and functional results of treatment of patients with such a pathology. However, strontium ranelate application efficiency with osteoporotic bone fractures patients requires further investigations.

About the authors

A. Y. Kochish

The Vreden Russian Research Institute of Traumatology and Orthopedics, St. - Petersburg

Author for correspondence.
Email: auk1959@mail.ru
Russian Federation

S. N. Ivanov

The Vreden Russian Research Institute of Traumatology and Orthopedics, St. - Petersburg

Email: 3000i@mail.ru
Russian Federation

D. V. Stafeev

The Vreden Russian Research Institute of Traumatology and Orthopedics, St. - Petersburg

Email: stafeevd@mail.ru
Russian Federation

T. B. Minasov

The Bashkir State Medical University, Ufa

Email: m004@yandex.ru
Russian Federation

References

  1. Беневоленская Л.И. Руководство по остеопорозу. М., 2003. 524 с.
  2. Кочиш А.Ю., Мироненко А.Н., Ласунский С.А. Стафеев Д.В. Возможности фармакологической коррекции постменопаузального остеопороза. пациенток с внесуставными переломами проксимального отдела бедренной кости. Травматология и ортопедия России. 2011; (2): 50-56.
  3. Лесняк О.М., Беневоленская Л.И., ред. Остеопороз: диагностика, профилактика и лечение. Клинические рекомендации. М.: Геотар-Медиа; 2009. 270 с.
  4. Лесняк О.М. Фармакоэкономика средств профилактики и лечения остеопороза. В кн.: Руководство по остеопорозу. М., 2003. с. 469-481.
  5. Минасов Т.Б., Минасов Б.Ш. Эффективность комбинированной терапии постменопаузального остеопороза с использованием препаратов двойного действия. Травматология и ортопедия России. 2011; (4): 92-94.
  6. Миронов С.П. Остеопороз как медико-социальная проблема. В кн.: Проблема остеопроза в травматологии. М.; 2006. с. 3.
  7. Ринге И.Д. Стероидный остеопороз. В кн.: Материалы XII Европейского Конгресса по ревматологии. Будапешт; 1991. с.1-3.
  8. Родионова С.С. Качество костной ткани как фактор риска переломов при остеопорозе. В кн.: Тезисы III конференции с международным участием. М.; 2006. с. 4.
  9. Рожинская Л.Я. и др. Результаты Российского многоцентрового исследования эффективности стронция ранелата у женщин с постменопаузальным остеопорозом. Остеопороз и остеопатии. 2007; (3): 25-30.
  10. Рожинская Л.Я. Системный остеопороз. Практическое руководство для врачей. М.: Издатель Мокеев, 2000. 196 с.
  11. Франке Ю., Рунге Г. Остеопороз. М.: Медицина; 1995. 304 с.
  12. Холодова Е.А., Шепелькевич А.П., Забаровская З.В. Эндокринные остеопатии: особенности патогенеза, диагностики и лечения. Минск: Белпринт; 2006. 88 с.
  13. Alegre D.N., Ribeiro C., Sousa C. et al. Possible beneficial effects of strontium ranelate in complicated fractures of long bones. Rheumatol. Int. 2012; 32: 439-443.
  14. Arlot M.E., Jiang Y., Genant H.K. et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J. Bone Miner. Res. 2008; 23(2): 215-222.
  15. Baron R., Tsouderos Y. In vitro effects of S12911 —2 on osteoclast function and bone marrow macrophage differenciation. Eur. J. Pharmacol. 2002; 450: 11-17.
  16. Bonnelye E., Chabadel A., Saltel F. et al. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone. 2008; 42: 129-138.
  17. Brennan T.C., Rybchyn M.S., Green W. et al. Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br. J. Pharmacol. 2009; 157: 1291-1300.
  18. Busse B. et al. J. Bone Miner. Res. 2007; 22(Suppl. 1): S.484-S.485. Abstract W477.
  19. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am. J. Med. 1997; 103: 12S-17S.
  20. Deeks E.D., Dhillon S. Strontium ranelate. A Review of its use in the treatment of postmenopausal osteoporosis. Drugs. 2010; 70 (6): 733-759.
  21. European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2008). http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC2613968/ pdf/198_2008_Article_560.pdf.
  22. Fromigue O., Hay E., Barbara A. et al. Calcium sensing receptor dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate. J. Cell. Mol. Med. 2009; 13: 2189-2199.
  23. Habermann B., Kafchitsas K., Olender G. et al. Strontium ranelate enhances callus strength more than PTH 1 — 34 in an osteoporotic rat model of fracture healing. Calcif. Tissue Int. 2010; 86: 82-89.
  24. Hurtel-Lemaire A.S., Mentaverri R., Caudrillier A. et al. The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways. J. Biol. Chem. 2009; 284: 575-584.
  25. Kaufman J.M. et al. Osteoporos Int. 2011; 22(Suppl.1): S114-S115. Abstract OC41.
  26. Lehman R.A. Jr. Dmitriev A.E., Cardoso M.J. et al. Effect of teriparatide [Rh PTH (1, 34)] and calcitonin on intertransverse process fusion in a rabbit model. Spine. 2010; 35: 146-152.
  27. Li Y., Feng G., Gao Y. et al. Strontium ranelate treatment enhances hydroxyapatite-coated titanium screws fixation in osteoporotic rats. J. Orthop. Res. 2010; 28: 578-582.
  28. Li Y., Luo E., Feng G. et al. Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats. Osteoporosis Int. 2010; 21: 1889-1897.
  29. Maimoun L., Brennan T.C., Badoud I. et al. Strontium ranelate improves implant osseointegration. Bone. 2010; 46: 1436-1441.
  30. Marie P.J., Ammann P., Boivin G. et al. Mechanisms of action and therapeutic potential of strontium in bone. Calcif. Tissue Int. 2001; 69: 121-129.
  31. Mashiba T., Hirano T., Turner C.H. et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J. Bone Miner Res. 2000; 15: 613-620.
  32. Mentaverri R., Yano S., Chattopadhyay N. et al. The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis. FASEB J. 2006; 20: 2562-2564.
  33. Meunier P.J., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 2004; 350: 459-468.
  34. Reginster J.Y., Kaufman J.M., Goemaere S. et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int. 2012; 23(3): 1115-1122.
  35. Register J.Y., Seeman E., De Vernejoul M.C. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 2005; 90(5): 2816-2822.
  36. Rizzoli R., Bruyere O., Cannata-Andia J.B. et al. Management of osteoporosis in the elderly. Curr. Med. Res. Opin. 2009; 25(10): 2373-2387.
  37. Salvin S., Quartuccio L., Maset M. Strontium ranelate and femural fracture healing during rheumaatoid arthritis and osteoporosis. Bone. 2009; 45: S.143.
  38. Sambrook P., Cooper C. Osteoporosis. Lancet. 2006; 367: 2010-2018.
  39. Segal E., Zinman C., Raz B. et al., Low patient compliance — a major negative factor in achieving vitamin D adequacy in elderly hip fracture patients supplemented with 800 IU of vitamin D3 daily. Arch Gerontol. Geriatr. 2009; 49(3): 364-367.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies